If the dental bill has ever made you gulp, you’re far from alone. Around three in ten Australian adults say they avoid or delay dental care due to costs. In Aotearoa New Zealand, almost half of adults ...

Scientists are making rapid progress toward a long-awaited goal that could help to reshape cancer care: mRNA cancer vaccines with the potential to significantly boost the immune system's ability to ...

The belief that surgery spreads cancer is a common public misconception. Onco-surgeon Yogeshwar Shukla spoke to Free Press on cancer treatment and misconceptions. Excerpts: There is a perception that ...

Talquetamab delivers high response rates in refractory myeloma; learn how to prevent skin, nail and oral side effects to stay on therapy. As the therapeutic arsenal for relapsed/refractory multiple ...

Objective: To evaluate the percentage variation of the different therapeutic modalities used in new cases of cancer, before and during the pandemic, in Ceará. Methods: Descriptive study with ...

Aparna Srivastava raised eyebrows for her baffling medical advice and even told one patient to eat a particular type of ...

Equity-Insider.com News Commentary -- Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing rounds already closing ...

Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted ...

Icotrokinra is a once-daily, empty-stomach oral peptide that antagonizes IL‑23R, aiming to match biologic pathway selectivity while overcoming historic oral peptide bioavailability barriers. Duplicate ...

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced it will ...

Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program and translational research in aerodigestive cancers, outlined in an interview ...